Travere Therapeutics: Still Undervalued Post FSGS Approval [Seeking Alpha]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Seeking Alpha
TVTX remains undervalued, with projected peak sales of $2.2–3B across FSGS and IgAN, and a forward PE of 8.84 versus a sector median of ~18. Filspari's commercial launch benefits from cross-selling synergies with IgAN, leveraging existing infrastructure to accelerate FSGS market penetration and reduce costs. Key risks include commercial execution, rising IgAN competition, and patent expiration, but FSGS exclusivity and orphan drug protections extend into 2030–2033. Getty Images Travere Therapeutics overview In my previous article titled "Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think", I explained why I believe Filspari will be approved for FSGS. Recently that approval came, and TVTX stock shot up on the news. In This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of TVTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opin
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Purespring announces publication of notable study highlighting an under recognised genetic driver of adult-onset FSGS, in particular in US and UK populations [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics to Report First Quarter 2026 Financial ResultsBusiness Wire
- Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now? [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics (TVTX) had its "buy" rating reaffirmed by Guggenheim.MarketBeat
- Is It Time To Reassess Travere Therapeutics (TVTX) After Its Recent Price Surge [Yahoo! Finance]Yahoo! Finance
TVTX
Earnings
- 2/19/26 - Beat
TVTX
Sec Filings
- 4/23/26 - Form 4
- 4/22/26 - Form 144
- 4/16/26 - Form 4
- TVTX's page on the SEC website